Stella Stergiopoulos

4 weeks ago | onlinelibrary.wiley.com | Adam Brufsky |Rickard Sandin |Stella Stergiopoulos |Connie Chen

1 Introduction Incidence rates of invasive breast cancer (BC) in the United States have increased since the mid-2000s, and BC is the second-leading cause of cancer-related death in women [1].

Jul 25, 2024 | cancernetwork.com | Heather Moore |Avirup Guha |Irene Arias |Stella Stergiopoulos |Benjamin Li |Michael G. Fradley | +3 more

BackgroundThe prevalence of preexisting cardiovascular (CV) comorbidities at diagnosis of hormone receptor-positive (HR+)/HER2-negative (HER2–) metastatic breast cancer (mBC) has not been well established. We aimed to describe the prevalence of preexisting CV comorbidities in patients with newly diagnosed HR+/HER2– mBC and to describe the first documented cancer treatment and concurrent medications with risk of QT interval (QTc) prolongation for patients with or without CV comorbidities.